Circulating Tumor Cells

BreastCancer_Metastasis_700x233

Towards personalized cancer care: liquid biopsy for monitoring primary breast cancer

Breast cancer is the most common cancer in women, accounting for 23% of all cancer diagnoses (1). At the time of diagnosis, a majority of patients (>90%) will have localized disease, which is typically treated with surgery, radiation and therapeutic agents. Localized disease is associated with improved five-year survival rates, relative to more advanced cancers… Read article →


CirculatingTumorCells_700x233

HER2-positive circulating tumor cells in primary breast cancer patients with HER2-negative tumors

In metastatic breast cancer patients, the presence of circulating tumor cells (CTCs) in the blood predicts shorter progression-free survival and lower overall survival (1). Persistent CTCs after treatment also predict a lack of therapeutic response (2). Although the prognostic significance of CTCs in metastatic patients is well established, fewer studies have examined CTCs in primary… Read article →




BreastCancer_Metastasis_700x233

CTCs as prognostic markers for metastatic breast cancer

Circulating tumor cells (CTCs) are tumor cells circulating freely in the peripheral blood of patients. The characterization of CTCs is considered as a real-time “liquid biopsy” that provides an ongoing picture of a patient’s cancer status, offering valuable insight into personalized anticancer therapy. CTCs are very rare and highly heterogeneous, possessing tumor-specific antigenic and genetic characteristics. One… Read article →